Asuragen, a provider in the development of molecular diagnostics, had received notices of allowance from the US Patent and Trademark Office (USPTO) for claims related to the use of mir-21 and mir-30a as diagnostics in lung cancer.
miR-21 has been implicated as a possible therapeutic target and in several clinically relevant diagnostic applications, including potential improvements in early detection and more informed prognosis of lung cancer.
Human miR-21 acts as a marker for use as a diagnostic for lung cancer as it will be highly expressed in lung cancer compared to normal patients.
Asuragen plans to launch its first miRNA kit, a miR-21 (RUO) kit for the detection of mir-21 expression levels, in the second quarter of this year.
Asuragen CEO and CSO Matt Winkler said they were the first company to launch a clinically validated miRNA-based diagnostic test and now are poised to launch their first miRNA-based detection kit.
"We are beginning to see a steady stream of allowances from our early miRNA patent filings which highlight our early pioneering work in the development of microRNA technologies for health care applications," Winkler said.